FOR IMMEDIATE RELEASE

CONTACT:
David E. Doolittle
Public & Investor Relations
404-840-1321
david_e_doolittle@yahoo.com

Transfusion & Transplantation Technologies LLC
President, CEO
678-860-3725
tawalts@yahoo.com

Transfusion & Transplantation Technologies Secures Over $300K In Outside Financing

Will help accelerate Aegis blood analyzer development ahead of anticipated Series A financing

ATLANTA, GA – August 24, 2007 – Transfusion & Transplantation Technologies LLC (“3Ti”), developer of “next generation” automated blood analyzer technology for the pre-transfusion (immunohematology) diagnostics market, announced today the securing of over $300,000 in outside financing from two different sources. “This financing will be used in part to help accelerate software and hardware development of 3Ti’s Aegis automated blood analyzer and associated consumables ahead of close of an anticipated “Series A” financing initiated this month,” said Terry Walts, president and CEO of 3Ti.

Over $200,000 of this financing was sourced through accredited individual investors participating in the Company’s first outside (i.e., non-research grant, non-award) funding. In addition, 3Ti was notified in late July by the Georgia Research Alliance (“GRA”) that it had been awarded a Phase IIIA $100,000 investment in the form of a non-collateralized loan. The GRA’s Phase III program, which began in 2006, targets Georgia based and headquartered companies developing technologies licensed from university research in one of Georgia’s strategic industries. Companies must also have had limited institutional venture capital investment to date. 3Ti may also be eligible to receive a subsequent round of up to $150,000 in a GRA Phase IIIIB investment at a future date on terms substantially similar to the Phase IIIA investment, though there currently is no explicit or implied obligation on the part of GRA or the Company to pursue this second investment at this time.

About Transfusion & Transplantation Technologies, LLC

Founded in 2000 by two distinguished physician-scientists at Emory University, Transfusion & Transplantation Technologies LLC is a medical device company developing “next generation” fully-automated blood bank multianalyzer technology for the pre-transfusion (immunohematology) diagnostics market. In late 2006 the Company won the “Early Stage Company Shootout” competition at the prestigious SEBIO Investor Forum. 3Ti's first product, the Aegis blood analyzer is being designed to perform routine blood typing, antibody screening, cross-matching and certain other tests “faster, better and more efficiently” than competitive analyzers and/or manual testing today. In addition, it is anticipated that the Aegis technology based on flow cytometry and novel multifunctional flexible architecture will help automate certain manual blood assays that have not been automatable to date as well as certain new and emerging new tests and testing platforms. The Company believes that its Aegis technology has the potential over time to become the standard of care in pre-transfusion (immunohematology) blood bank testing worldwide. For more information about Transfusion & Transplantation Technologies, contact David Doolittle or the Company directly.
Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company’s technologies, investment in product development, possible future financings or other activities and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” “potential,” or similar expressions. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.